Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infectionResearch Article Published on 2021-08-272022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] acute COVID-19 administration analyzed antibodies antibody antigenic baseline binding children children with MIS-C clinical response collected coronavirus coronavirus disease correlated correlation COVID-19 determine dose Effect Endemic GMT group healthy children healthy control healthy controls HKU1 Hospitalized IgG antibody Immunity Inflammatory injected injection intramuscular intramuscularly mice MIS-C murine Neutralizing neutralizing antibody Neutralizing antibody response objective original regimen response Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralization SARS-CoV-2 spike SARS-CoV-2 spike protein Serologic response significantly higher spike IgG Spike protein syndrome [DOI] 10.1371/journal.pone.0256482 PMC 바로가기 [Article Type] Research Article
Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapyResearch Article Published on 2021-08-052022-10-31 Journal: eLife [Category] COVID-19, MERS, SARS, [키워드] Algorithm Analysis Cancer therapy CD4+ cell CD4+ T cell Cell cells changes in Chemotherapy clinical response comparable Complete COVID-19 COVID-19 patient Cytometry Disease progression emerging disease example homogeneous hotspot Human identify immune Immune cell immune changes Immune monitoring immune system immunology individual donor Infection inhibitor knowledge leukemia machine learning magnitude Melanoma MHCII Other Patient phenotype Post-infection provided reagent repeated reveal rhinovirus SARS-CoV-2 infections Single Cell subset Systems biology therapy trajectory virus virus-specific T cell [DOI] 10.7554/eLife.64653 PMC 바로가기 [Article Type] Research Article
Large variations in disease severity, death and ICU admission of 2993 patients infected with SARS-CoV-2: The potential impact of genetic vulnerabilitySARS-CoV-2에 감염된 2993명의 환자의 질병 중증도, 사망 및 ICU 입원의 큰 변화: 유전적 취약성의 잠재적 영향Article Published on 2021-07-012022-09-11 Journal: Journal of infection and public health [Category] SARS, 치료기술, [키워드] affecting age clinical Clinical characteristics clinical response Containment country COVID-19 COVID-19 disease COVID-19 epidemic COVID-19 in patient COVID-19 infection COVID-19 pandemic COVID-19 symptom COVID-19 symptoms death directions disease severity Dubai epidemiological exploration First wave Gender Genetic genetic variability Genetic vulnerability symptoms. Genomics Healthcare systems higher risk Hospitalization ICU admission India individual infected with COVID-19 Infection less Patient predictor Severe case Society Spectrum susceptibility Symptoms Treatment Variation virus vulnerability [DOI] 10.1016/j.jiph.2021.04.008 PMC 바로가기 [Article Type] Article
Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional StudyArticle Published on 2021-06-232022-10-27 Journal: Antibiotics [Category] COVID-19, [키워드] bacterial co-infection Bacterial infection bloodstream infection BSI Ceftaroline characteristics of patients clinical response Combination conducted coronavirus disease COVID-19 COVID-19 patients cross-sectional Diagnosis etiological hospital Hospitalized Improving indication Italy monotherapy MOST MRSA pandemic Patient patients patients with COVID-19 Pneumonia receiving Registered single-center Staphylococcus aureus therapy was used were given [DOI] 10.3390/antibiotics10070763 PMC 바로가기 [Article Type] Article
Oral nano‐curcumin formulation efficacy in the management of mild to moderate outpatient COVID‐19: A randomized triple‐blind placebo‐controlled clinical trialOriginal Research Published on 2021-06-192022-10-31 Journal: Food Science & Nutrition [Category] COVID-19, [키워드] anti‐inflammatory baseline Cell cellular signaling pathways chills clinical response clinical trial coronavirus disease Coronavirus disease 2019 cough COVID‐19 COVID‐19 patient COVID‐19 CRP Curcumin Efficacy Efficacy and safety encapsulation evaluated faster gel IMPROVE inclusion criteria inhibiting laboratory data Lymphocyte count management Mild moderate modulating oral Patient Placebo Placebo‐controlled potential treatment option protease Randomized Randomly receive reported resolved Result Sample size Serum level significantly significantly higher sore throat Symptom Treatment treatment group two groups virus were assessed [DOI] 10.1002/fsn3.2226 PMC 바로가기 [Article Type] Original Research
Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workersSARS-COV-2 SEROCONVERSION (PASS) 연구의 전향 적 평가 : 의료 근로자의 SARS-COV-2 감염 및 예방 접종에 대한 관찰 코호트 연구Study Protocol Published on 2021-06-092022-09-01 Journal: BMC Infectious Diseases [Category] MERS, SARS, 진단, [키워드] Affect Analysis Anti-spike antibody assessment Asymptomatic baseline clinical response Cohort Complete conducted coronavirus coronavirus disease Coronavirus disease 2019 CoV covariates COVID-19 COVID-19 disease COVID-19 disease course cross-reactivity cytokine production determine develop disease symptoms evaluate Frequency glycoprotein HCoV HCoV-229E HCoV-HKU1 HCoV-NL63 HCoV-OC43 HCoVs HCWs healthcare healthcare worker HKU1 human coronavirus IgG antibodies IgM and IgG immune response immune responses Immune-response immunological individual Infection intensity Killer cell magnitude mononuclear cell natural natural killer cell NL63 number of infected Observational cohort study OC43 pandemic coronavirus participant pauci-symptomatic PBMCs peptide peptide pool performed Peripheral blood Peripheral blood mononuclear cells positive Prospective Prospective Study questionnaire receive respiratory Respiratory disease Respiratory illness SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 PCR testing SARS-CoV-2 vaccination SARS-CoV-2 vaccine seroconvert serology analysis severe respiratory illness severity Spike proteins supplementary material Symptom T cell T cell activation T cell response T cell responses tested the SARS-CoV-2 the spike protein vaccination Vaccine viral respiratory with COVID-19 [DOI] 10.1186/s12879-021-06233-1 PMC 바로가기 [Article Type] Study Protocol
COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two casesClinical Trial Published on 2021-05-012022-10-05 Journal: Strahlentherapie Und Onkologie [Category] SARS, 임상, [키워드] acute respiratory syndrome benefit candidate clinical response clinical trial coronavirus disease COVID-19 COVID-19 pneumonitis Cytokine storm diagnosed with COVID-19 discharged dose effort Healthcare system hospital Inflamatory response Inflammatory response Invasive mechanical ventilation less life-threatening lung outbreak outcome pandemic Patient Pneumonia Prospective Study Radiation radiological Radiotherapy reducing resulting risk SARS-CoV-2 Symptoms therapy treated treating COVID-19 Treatment [DOI] 10.1007/s00066-020-01743-4 PMC 바로가기 [Article Type] Clinical Trial
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experienceCase Reports Published on 2021-05-012022-10-05 Journal: Rheumatology International [Category] SARS, 임상, [키워드] adjusted affected ankylosing spondylitis Arthritis Autoimmune rheumatic disease biologic changed clinical manifestation clinical response Comorbidity COVID-19 COVID-19 disease course disease course disease-modifying anti-rheumatic drug drug Drug side effect expressed Follow-up General population hospital Inflammatory arthritis investigated Laboratory mild COVID-19 symptoms olfactory dysfunction outcome Patient Pneumonia prospective observational study psoriatic arthritis receiving recorded respiratory symptom rheumatic disease Rheumatoid rheumatoid arthritis SARS-COV-2 infection single-center sore throat spondylitis systemic manifestation treated Treatment [DOI] 10.1007/s00296-021-04818-2 PMC 바로가기 [Article Type] Case Reports
Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation기계적 환기가 아닌 SARS-Cov-2 감염 환자에서 룩소리티닙의 동정적 사용: 염증 및 환기에 대한 단기 영향Article Published on 2021-05-012022-09-11 Journal: Clinical and translational science [Category] SARS, 신약개발, [키워드] accompany affected Anti-inflammatory anti-inflammatory drug anti-inflammatory effect Antiviral appear approach baseline benefit Biomarkers biomarkers of inflammation C-reactive protein C-reactive protein (CRP Chain Reaction clinical pharmacology clinical response collected compassionate use compassionate-use contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection criteria CRP Cytokines during treatment Dyspnea Effect effective Evidence hyperinflammation Hypothesis immune cells inclusion criteria Infection Inflammation Inflammatory response inhibit interferons interstitial pneumonia invasive ventilation JAK inhibitor jak inhibitors Jak-STAT janus Janus kinase less Lungs management mechanical ventilation mmHg need for oxygen oxygen oxygen saturation oxygen support PaO pathway Patient patients hospitalized patients with SARS-CoV-2 polymerase chain polymerase chain reaction positive present pro-inflammatory pro-inflammatory cytokines prognostic progression provided reduce reduced reduction reinforcement respiratory Respiratory function ruxolitinib SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome Side effect significantly more STAT Support Symptom systemic inflammation target the disease therapeutic therapeutic agent therapeutic agents Topic Treatment type I interferon type I interferons Ventilation were recorded [DOI] 10.1111/cts.12971 PMC 바로가기 [Article Type] Article
Inferring UK COVID‐19 fatal infection trajectories from daily mortality data: Were infections already in decline before the UK lockdowns?Biometric Practice Published on 2021-04-072022-10-28 Journal: Biometrics [Category] COVID-19, MERS, SARS, [키워드] Analysis applied approach assumption available data Bayesian clinical response coronavirus disease Course COVID‐19 death dependent on distribution effective Epidemic epidemiological example fatal infection Infection Intervention lockdown lockdown efficacy lockdown impact management Mortality NPI Observational data occurred per day random Reproduction number required SARS‐CoV‐2 semiparametric subject subsequent the disease trajectory [DOI] 10.1111/biom.13462 PMC 바로가기 [Article Type] Biometric Practice